Early initiation of eculizumab therapy for Streptococcus pneumoniae-associated hemolytic uremic syndrome

Pediatr Blood Cancer. 2021 Feb;68(2):e28589. doi: 10.1002/pbc.28589. Epub 2020 Jul 16.

Authors

Jhoclay See¹, Raed Bou Matar², Orkun Baloglu¹, Samir Q Latifi¹, Ravi Talati³, Hemant S Agarwal¹

Affiliations

¹ Department of Pediatric Critical Care, Cleveland Clinic Children's, Cleveland, Ohio.
² Center for Pediatric Nephrology, Cleveland Clinic Children's, Cleveland, Ohio.
³ Pediatric Hematology Oncology and Blood and Bone Marrow Transplantation, Cleveland Clinic Children's, Cleveland, Ohio.

PMID: 32672848
DOI: 10.1002/pbc.28589

No abstract available

Keywords: Streptococcus pneumoniae-associated hemolytic uremic syndrome; complement; eculizumab.

Publication types

Case Reports
Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Child, Preschool
Complement C5 / drug effects
Complement Inactivating Agents / therapeutic use*
Female
Hemolytic-Uremic Syndrome / drug therapy*
Hemolytic-Uremic Syndrome / microbiology
Hemolytic-Uremic Syndrome / pathology
Humans
Streptococcus pneumoniae / drug effects*

Substances

Anti-Bacterial Agents
Antibodies, Monoclonal, Humanized
Complement C5
Complement Inactivating Agents
eculizumab